Advertising Disclaimer
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemanske, R. F.
Right arrow Articles by Gupta, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemanske, R. F., Jr
Right arrow Articles by Gupta, N.
Related Collections
Right arrow Allergy & Dermatology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 110 No. 5 November 2002, pp. e55

ELECTRONIC ARTICLE

Omalizumab Improves Asthma-Related Quality of Life in Children With Allergic Asthma

Robert F. Lemanske, Jr, MD*, Anjuli Nayak, MD{ddagger}, Margaret McAlary, MS§, Francois Everhard, MS||, Angel Fowler-Taylor, RPh§, Niroo Gupta, MD, PhD§

* University of Wisconsin, Madison, Wisconsin
{ddagger} University Of Illinois, Peoria, Illinois
§ Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
|| Novartis Pharma AG, Basel, Switzerland

--> Background and Objective. Omalizumab is a recombinant, humanized, monoclonal anti-immunoglobulin E (IgE) antibody, developed for the treatment of IgE-mediated diseases. In children with allergic asthma, it was shown to reduce the requirement for inhaled corticosteroids while protecting against disease exacerbation. Here we report the effects of treatment with omalizumab on asthma-related quality of life (AQoL) in children with allergic asthma.

Methods. This evaluation was part of a previously reported 28-week, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of omalizumab (at least 0.016 mg/kg/IgE [IU/mL] per 4 weeks) in children with allergic asthma who were well controlled on daily treatment with inhaled corticosteroids. Dosage of beclomethasone dipropionate was kept constant for 16 weeks (steroid-stable phase), then reduced over 8 weeks to the minimum effective dose (steroid-reduction phase). This dose was then maintained for the final 4 weeks. The Pediatric Asthma Quality of Life Questionnaire (PAQLQ) was administered at baseline, week 16, and week 28.

Results. Baseline demographics, PAQLQ scores, and other data were comparable for the 2 treatment groups. At the end of the steroid-reduction phase, patients in the omalizumab-treated group reported significant improvements in the "activities" and "symptoms" domain scores as well as overall AQoL compared with placebo. More patients in the omalizumab group achieved clinically relevant (>=0.5) changes in PAQLQ scores during the course of the study, and this difference was significant for activities and overall AQoL.

Conclusion. Omalizumab improves AQoL in children with allergic asthma.

Key Words: allergic asthma • IgE • omalizumab • children • quality of life • asthma

Abbreviations: QoL, quality of life • PAQLQ, Pediatric Asthma Quality of Life Questionnaire • IgE, immunoglobulin E • AQoL, asthma-related quality of life • BDP, beclomethasone dipropionate

Received for publication Feb 27, 2002; Accepted Jul 24, 2002.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
M. E. Wechsler, D. A. Wong, M. K. Miller, and L. Lawrence-Miyasaki
Churg-Strauss Syndrome in Patients Treated With Omalizumab
Chest, August 1, 2009; 136(2): 507 - 518.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
L. Hendeles and C. A Sorkness
Anti-Immunoglobulin E Therapy with Omalizumab for Asthma
Ann. Pharmacother., September 1, 2007; 41(9): 1397 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H.J. Bueving, J.C. van der Wouden, H. Raat, R.M.D. Bernsen, J.C. de Jongste, L.W.A. van Suijlekom-Smit, A.D.M.E. Osterhaus, G.F. Rimmelzwaan, M. R.-v. Molken, and S. Thomas
Influenza vaccination in asthmatic children: effects on quality of life and symptoms
Eur. Respir. J., December 1, 2004; 24(6): 925 - 931.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
S. T Holgate
The epidemic of asthma and allergy
J R Soc Med, March 1, 2004; 97(3): 103 - 110.
[Full Text] [PDF]

Home page
 Evid. Based Nurs.Home page
OTHER ARTICLES NOTED (24 Jan 03 to 18 Apr 03)
Evid. Based Nurs., July 1, 2003; 6(3): e1 - 12.
[Full Text] [PDF]